Altamira Therapeutics Ltd.
Performance History
| Key Stats | |
|---|---|
| Open | $0.77 |
| Prev. Close | $0.64 |
| EPS | -22.56 |
| Dividend | $0.00 |
| Next Earnings Date | Apr 12, 2022 |
| Dividend Yield % | - |
| Market Cap | $3.11M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 0.34 | 0.86 |
| 52 Week Range | 0.09 | 6.09 |
| Ratios | |
|---|---|
| P/B Ratio | 0.35 |
| Revenue | - |
| Operating M. % | -4,348.49% |
| Earnings | - |
| Earnings Growth % | - |
| EBITDA Margin % | - |
| ROE % | -964.17% |
| EPS | -22.56 |
Score Breakdown
All Score (37 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| CYTO | Market | |
|---|---|---|
| Value | 63 | 42 |
| Quality | 34 | 46 |
| Ownership | 0 | 39 |
| Growth | 21 | 44 |
| Dividends | - | 32 |
All Score (37 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Altamira Therapeutics Ltd. (CYTO)
Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is headquartered in Hamilton, Bermuda.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Thomas Meyer Ph.D.
- Headquarters
- Hamilton
- Employees
- 16
Keep an eye on Altamira Therapeutics Ltd.
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.